Linerixibat

Linerixibat
Clinical data
Trade names	Lynavoy
Other names	GSK-2330672
AHFS/Drugs.com	lynavoy
License data	US DailyMed: Linerixibat;
Drug class	Ileal bile acid transporter inhibitor
ATC code	A05AX08 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	1345982-69-5;
PubChem CID	53492727;
DrugBank	DB11729;
ChemSpider	30825906;
UNII	386012Z45S;
KEGG	D11539;
ChEMBL	ChEMBL2387408;
Chemical and physical data
Formula	C28H38N2O7S
Molar mass	546.68 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCC[C@@]1(CS(=O)(=O)C2=C(C=C(C(=C2)CNC(CC(=O)O)CC(=O)O)OC)[C@H](N1)C3=CC=CC=C3)CC;
	InChI InChI=1S/C28H38N2O7S/c1-4-6-12-28(5-2)18-38(35,36)24-13-20(17-29-21(14-25(31)32)15-26(33)34)23(37-3)16-22(24)27(30-28)19-10-8-7-9-11-19/h7-11,13,16,21,27,29-30H,4-6,12,14-15,17-18H2,1-3H3,(H,31,32)(H,33,34)/t27-,28-/m1/s1; Key:CZGVOBIGEBDYTP-VSGBNLITSA-N;

Linerixibat, sold under the brand name Lynavoy, is a medication used for the treatment of cholestatic pruritus. Linerixibat is an ileal bile acid transporter (IBAT) inhibitor.^[2]

Other namesGSK-2330672

Quick facts Clinical data, Trade names ...

Close

Linerixibat was approved for medical use in the United States in March 2026.^[1]^[3]^[4]

Medical uses